Functional imaging in drug discovery and development

被引:0
作者
Schmidt, ME [1 ]
Wang, LQ [1 ]
机构
[1] Novartis Pharma AG, Clin Imaging Unit, CH-4057 Basel, Switzerland
关键词
drug development; magnetic resonance imaging; positron emission tomography;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The use of in vivo imaging with radioisotope- and magnetic resonance-based methods is increasing for all stages of drug development. The primary role for these methods has, and continues to be, clinical diagnosis, although the technology itself is highly versatile and can be adapted to very different applications. Techniques may be developed to measure the drug target, tissue-specific drug disposition and action, and to pursue basic investigations of the pathophysiology of disease. The sensitivity, spatial resolution, temporal resolution and frequency of measurement with radioisotope and magnetic resonance imaging are significantly different. Whether the application is related to the drug target, action or disease response, must first be considered before selecting which functional imaging approach can be used.
引用
收藏
页码:497 / 501
页数:5
相关论文
共 8 条
  • [1] Imaging amyloid-β deposits in vivo
    Bacskai, BJ
    Klunk, WE
    Mathis, CA
    Hyman, BT
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2002, 22 (09) : 1035 - 1041
  • [2] Diffusion MRI for prediction of response of rectal cancer to chemoradiation
    Dzik-Jurasz, A
    Domenig, C
    George, M
    Wolber, J
    Padhani, A
    Brown, G
    Doran, S
    [J]. LANCET, 2002, 360 (9329) : 307 - 308
  • [3] Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: A fluorine MRS study
    Henry, ME
    Moore, CM
    Kaufman, MJ
    Michelson, D
    Schmidt, ME
    Stoddard, E
    Vuckevic, AJ
    Berreira, PJ
    Cohen, BM
    Renshaw, PF
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (09) : 1506 - 1508
  • [4] Pharmacokinetics of radiolabelled anticancer drugs for positron emission tomography
    Hutchinson, OC
    Collingridge, DR
    Barthel, H
    Price, PM
    Aboagye, EO
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (11) : 917 - 929
  • [5] Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low
    Rabiner, EA
    Bhagwagar, Z
    Gunn, RN
    Sargent, PA
    Bench, CJ
    Cowen, PJ
    Grasby, PM
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (12) : 2080 - 2082
  • [6] Functional MRI detection of pharmacologically induced memory impairment
    Sperling, R
    Greve, D
    Dale, A
    Killiany, R
    Holmes, J
    Rosas, HD
    Cocchiarella, A
    Firth, P
    Rosen, B
    Lake, S
    Lang, N
    Routledge, C
    Albert, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (01) : 455 - 460
  • [7] 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)
    Stroobants, S
    Goeminne, J
    Seegers, M
    Dimitrijevic, S
    Dupont, P
    Nuyts, J
    Martens, M
    van den Borne, B
    Cole, P
    Sciot, R
    Dumez, H
    Silberman, S
    Mortelmans, L
    van Oosterom, A
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (14) : 2012 - 2020
  • [8] How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development
    Workman, P
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (11) : 891 - 902